Last A$0.27 AUD
Change Today 0.00 / 0.00%
Volume 500.0
ELX On Other Exchanges
Symbol
Exchange
OTC US
Berlin
As of 11:34 PM 12/21/14 All times are local (Market data is delayed by at least 15 minutes).

ellex medical lasers ltd (ELX) Snapshot

Open
A$0.27
Previous Close
A$0.27
Day High
A$0.27
Day Low
A$0.27
52 Week High
01/22/14 - A$0.47
52 Week Low
12/18/14 - A$0.23
Market Cap
29.1M
Average Volume 10 Days
18.6K
EPS TTM
A$0.0076
Shares Outstanding
107.6M
EX-Date
12/3/02
P/E TM
35.5x
Dividend
--
Dividend Yield
--
Current Stock Chart for ELLEX MEDICAL LASERS LTD (ELX)

Related News

No related news articles were found.

ellex medical lasers ltd (ELX) Related Businessweek News

No Related Businessweek News Found

ellex medical lasers ltd (ELX) Details

Ellex Medical Lasers Limited designs, manufactures, markets, and sells lasers and ultrasound systems for ophthalmologists to diagnose and treat eye diseases. The company offers selective laser trabeculoplasty (SLT)/YAG combination laser systems for the SLT treatment in glaucoma patients under the Tango and Solo names: iTRACK 250 microcatheter for the treatment of open-angle glaucoma; and Ultra Q Reflex, a multi-modality YAG laser with intraocular lenses (IOL), peripheral iridotomy for glaucoma, and YAG laser vitreolysis for the treatment of floaters. It also provides capsulotomy Ultra Q Reflex multi-modality YAG laser for the treatment of vitreous strands and opacities; Ultra Q, a microsurgical YAG laser for IOL-friendly photodisruption; and Super Q, a YAG laser to correct myopia or hyperopia. In addition, the company offers photocoagulators, including Solitaire, a portable green laser for the treatment of retinal disease; Integre Pro, a laser for use in the diagnosis and treatment of retinal disease; and Rapide, a pattern scanning photocoagulator. Further, it provides Eye Cubed, a diagnostic ultrasound system for the posterior and anterior segments of an eye. Additionally, the company is developing Retinal Rejuvenation Therapy, a non-thermal laser therapy for the treatment of diabetic retinopathy and age-related macular degeneration. It also offers a range of third-party medical devices and technologies. The company sells its products directly to end-user customers, as well as through independent third-party distributors in Australia, the United States, Europe, the Middle East, Asia, South America, and internationally. Ellex Medical Lasers Limited is headquartered in Adelaide, Australia.

221 Employees
Last Reported Date: 08/28/14

ellex medical lasers ltd (ELX) Top Compensated Officers

Group Chief Executive Officer
Total Annual Compensation: A$248.2K
Founder, Executive Chairman, Technical Direct...
Total Annual Compensation: A$45.0K
Vice President of Adavnced Research
Total Annual Compensation: A$180.9K
Compensation as of Fiscal Year 2014.

ellex medical lasers ltd (ELX) Key Developments

Ellex Medical Lasers Ltd Provides Earnings Guidance for the First Half of Fiscal 2014

Ellex Medical Lasers Ltd. expect an increase in revenue for the first half of approximately 15% compared with the first half of fiscal year 2014, along with a corresponding increase in EBITDA, provided current sales trends continue and production runs to schedule.

Ellex Medical Lasers Limited, Annual General Meeting, Nov 26, 2014

Ellex Medical Lasers Limited, Annual General Meeting, Nov 26, 2014., at 14:00 Cen. Australia Standard Time. Location: at BioSA Incubator Conference Centre, 40-46 West Thebarton Road. Agenda: To consider accounts & reports; to consider re-election of director; to adopt remuneration report.

Ellex Medical Lasers Limited Reports Audited Consolidated Earnings Results for the Year Ended June 30, 2014

Ellex Medical Lasers Limited reported audited consolidated earnings results for the year ended June 30, 2014. For the year, the company reported revenue of AUD 54,378,000 against AUD 42,804,000 a year ago. Profit from before income tax was AUD 1,311,000 against AUD 140,000 a year ago. Profit attributable to members of the parent was AUD 788,000 against loss attributable to members of the parent of AUD 816,000 a year ago. Basic and diluted earnings per share were 0.73 cents against basic and diluted loss per share of 1.0 cents a year ago. Net cash provided by operating activities was AUD 2,704,000 against AUD 1,944,000 a year ago. Payment for acquisition of business was AUD 1,693,000. Payment for property, plant and equipment was AUD 1,017,000 against AUD 605,000 a year ago. Payment for intangible assets was AUD 80,000 against AUD 78,000 a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ELX:AU A$0.27 AUD 0.00

ELX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Carl Zeiss Meditec AG €21.42 EUR +0.83
Iridex Corp $8.75 USD -0.0614
Quantel SA €3.22 EUR -0.02
Synergetics USA Inc $4.21 USD -0.29
Topcon Corp ¥2,499 JPY -58.00
View Industry Companies
 

Industry Analysis

ELX

Industry Average

Valuation ELX Industry Range
Price/Earnings 31.8x
Price/Sales 0.5x
Price/Book 0.7x
Price/Cash Flow 11.3x
TEV/Sales 0.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ELLEX MEDICAL LASERS LTD, please visit www.ellex.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.